Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) SVP Sells $1,784,513.46 in Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) SVP Adam Veness sold 16,167 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the sale, the senior vice president directly owned 3,833 shares of the company’s stock, valued at approximately $423,086.54. The trade was a 80.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $109.60 on Friday. Dianthus Therapeutics, Inc. has a one year low of $19.84 and a one year high of $114.55. The stock’s fifty day moving average is $96.76 and its 200 day moving average is $82.61. The stock has a market cap of $5.99 billion, a P/E ratio of -26.41 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Dianthus Therapeutics by 4.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after acquiring an additional 618 shares during the period. American Century Companies Inc. raised its stake in Dianthus Therapeutics by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after purchasing an additional 6,323 shares during the period. Invesco Ltd. lifted its holdings in Dianthus Therapeutics by 31.1% in the 2nd quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock worth $390,000 after purchasing an additional 4,962 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in Dianthus Therapeutics by 14.5% in the 2nd quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after purchasing an additional 149,200 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics in the 2nd quarter worth approximately $27,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on DNTH shares. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush lifted their price target on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $124.27.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.